Literature DB >> 18039085

Treatment of cryptococcosis in the setting of HIV coinfection.

Thana Khawcharoenporn1, Anucha Apisarnthanarak, Linda M Mundy.   

Abstract

The HIV pandemic has been associated with a rise in the prevalence of primary and recurrent cryptococcosis. Evidence-based treatment algorithms exist for the use of antifungal drugs and maintaining normal intracranial pressure in HIV-infected hosts with cryptococcal meningitis. Further investigation is needed for the treatment of cases with refractory infections and cryptococcosis-related immune reconstitution syndrome, along with the optimal use of adjuvant therapies. Primary and secondary prevention strategies remain at the crux of global control strategies for cryptococcal disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18039085     DOI: 10.1586/14787210.5.6.1019

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  3 in total

1.  Monitoring and impact of fluconazole serum and cerebrospinal fluid concentration in HIV-associated cryptococcal meningitis-infected patients.

Authors:  W Manosuthi; P Chetchotisakd; T L Nolen; D Wallace; S Sungkanuparph; T Anekthananon; K Supparatpinyo; P G Pappas; R A Larsen; S G Filler; D Andes
Journal:  HIV Med       Date:  2009-12-08       Impact factor: 3.180

Review 2.  [Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine].

Authors:  C Lichtenstern; S Swoboda; M Hirschburger; E Domann; T Hoppe-Tichy; M Winkler; C Lass-Flörl; M A Weigand
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

3.  The environmental yeast Cryptococcus liquefaciens produces capsular and secreted polysaccharides with similar pathogenic properties to those of C. neoformans.

Authors:  Glauber R de S Araújo; Gustavo J C Freitas; Fernanda L Fonseca; Paulo Emilio C Leite; Gustavo Miranda Rocha; Wanderley de Souza; Daniel A Santos; Susana Frases
Journal:  Sci Rep       Date:  2017-04-25       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.